This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Iovance Biotherapeutics stock | $36.56

Own Iovance Biotherapeutics stock in just a few minutes.

Posted

Fact checked

Iovance Biotherapeutics, Inc is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Iovance Biotherapeutics employs 148 staff and has a market cap (total outstanding shares value) of USD$5.3 billion.

How to buy shares in Iovance Biotherapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Iovance Biotherapeutics. Find the stock by name or ticker symbol: IOVA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Iovance Biotherapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$36.56, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Iovance Biotherapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Iovance Biotherapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Iovance Biotherapeutics share price

Use our graph to track the performance of IOVA stocks over time.

Iovance Biotherapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$36.56
52-week range USD$18.7 - USD$41.49
50-day moving average USD$32.9177
200-day moving average USD$31.8731
Wall St. target price USD$43.36
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.308

Buy Iovance Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Iovance Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Iovance Biotherapeutics price performance over time

Historical closes compared with the close of $36.56 from 2020-11-16

1 week (2020-11-25) -3.64%
1 month (2020-11-06) -9.59%
3 months (2020-09-04) 19.28%
6 months (2020-06-05) 16.40%
1 year (2019-12-05) 47.00%
2 years (2018-12-04) 269.29%
3 years (2017-12-05) 337.84%
5 years (2015-12-04) 393.39%

Iovance Biotherapeutics financials

Gross profit TTM USD$0
Return on assets TTM -25.05%
Return on equity TTM -42.51%
Profit margin 0%
Book value $5.178
Market capitalisation USD$5.3 billion

TTM: trailing 12 months

Shorting Iovance Biotherapeutics shares

There are currently 12.9 million Iovance Biotherapeutics shares held short by investors – that's known as Iovance Biotherapeutics's "short interest". This figure is 7% down from 13.9 million last month.

There are a few different ways that this level of interest in shorting Iovance Biotherapeutics shares can be evaluated.

Iovance Biotherapeutics's "short interest ratio" (SIR)

Iovance Biotherapeutics's "short interest ratio" (SIR) is the quantity of Iovance Biotherapeutics shares currently shorted divided by the average quantity of Iovance Biotherapeutics shares traded daily (recently around 1.2 million). Iovance Biotherapeutics's SIR currently stands at 10.94. In other words for every 100,000 Iovance Biotherapeutics shares traded daily on the market, roughly 10940 shares are currently held short.

However Iovance Biotherapeutics's short interest can also be evaluated against the total number of Iovance Biotherapeutics shares, or, against the total number of tradable Iovance Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Iovance Biotherapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Iovance Biotherapeutics shares in existence, roughly 90 shares are currently held short) or 0.0946% of the tradable shares (for every 100,000 tradable Iovance Biotherapeutics shares, roughly 95 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Iovance Biotherapeutics.

Find out more about how you can short Iovance Biotherapeutics stock.

Iovance Biotherapeutics share dividends

We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.

Have Iovance Biotherapeutics's shares ever split?

Iovance Biotherapeutics's shares were split on a 1:100 basis on 26 September 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.

Iovance Biotherapeutics share price volatility

Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $18.7 up to $41.49. A popular way to gauge a stock's volatility is its "beta".

IOVA.US volatility(beta: 0.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.9647. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).

Iovance Biotherapeutics overview

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site